Dr. Jerome H. Goldschmidt Jr., MD

Dr. Goldschmidt practices at Blue Ridge Cancer Care in Blacksburg, Virginia.

Dr. Goldschmidt's NPI, 1962478164, was assigned on February 27, 2006. Dr. Goldschmidt graduated from University of North Carolina at Chapel Hill School of Medicine in 1998. Dr. Goldschmidt holds Virginia license 0101238483.

Dr. Goldschmidt's primary practice is Blue Ridge Cancer Care, at 2600 Research Center Dr, Blacksburg, VA 24060 in Montgomery County. The practice phone is (540) 982-0237.

Dr. Goldschmidt's primary practice is Blue Ridge Cancer Care in Blacksburg, Virginia. Dr. Goldschmidt is also affiliated with LewisGale Hospital Montgomery. The medical group on file is Blue Ridge Cancer Care. Dmand AI also links Dr. Goldschmidt to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldschmidt practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Goldschmidt's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Goldschmidt is licensed in Virginia.

CMS data shows 97,365 Medicare services from Dr. Goldschmidt across 66 procedure codes in 2024, for 939 Medicare patients. Medicare paid $1,326,294 for them. Every service was in an office.

CMS counts 939 Medicare patients who saw Dr. Goldschmidt in 2024. The largest group is 65 to 74, with 398 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldschmidt's median patient age at 69, with 52% women.

In 2024, Dr. Goldschmidt wrote 2,059 Medicare Part D claims for 312 patients. 81% of them were for generic drugs. CMS names the drug for 1,701 of them, across 49 drugs with 11 or more claims each, at $4,547,462 in total drug cost. In 2023, CMS named 1,660 claims across 51 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Goldschmidt for performance year 2024, reported through an alternative payment model (APM). Dr. Goldschmidt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldschmidt as offering telehealth.

CMS Open Payments shows 714 general payments to Dr. Goldschmidt from 63 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 36% of the total. Bristol-Myers Squibb Company paid the most, $55,112. It also lists 4 research payments totaling $24,773 from 2019 to 2020.

Dr. Goldschmidt graduated from University of North Carolina at Chapel Hill School of Medicine in 1998.